

# WYOMING STATE BOARD OF PHARMACY

## Board Meeting Minutes June 25 and 26, 2008

Wednesday, June 25, 2008:

Present/Absent	Board Member	Title
present	Randolph A. Harrop, R.Ph.	Board President
present	Alison Kay McManus, R.Ph.	Board Vice President
present	Terry L. Carr, R.Ph.	Board Secretary/Treasurer
present	Robert J. (Rick) Davis, M.D.	Board Member
present	John R. McPherson, D.D.S.	Board Member
present	Jennifer S. Nevins, R.Ph.	Board Member
present	Gary W. Norwood, D.V.M.	Board Member
present	Charles W. Smith	Board Member
absent	Louann Weber, R.Ph.T.	Board Member, <i>ex-officio</i>

**Guests/Observers:**

Sarah Blakeley, R.Ph.	Cheyenne Regional Medical Center
Kara Beech, BS, CHC	Executive Director, Wyoming Pharmacy Association
H. Richard Burton, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy
Denise Embury	Records Analyst, Board of Pharmacy
Roxanne Homar, R.Ph.	State Pharmacist, Wyoming Department of Health
Eric Hunter	Intern; University of Wyoming PharmD Candidate
Ken F. Nelson, J.D.	Senior Assistant Attorney General
Patti Nelson, R.Ph.	Wyoming Medical Center
Jacqueline L. Seebaum	Executive Assistant, Board of Pharmacy
George A. Vandel, NCAC II, CAP	Executive Director, Wyoming Professional Assistance Program
Mary K. Walker, R.Ph.	Executive Director, Board of Pharmacy
Maddie Wyatt	University of Wyoming PharmD Candidate
Henry (Hank) York, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy

**Board Meeting Call to Order.** Mr. Harrop called the Board meeting to order at 1:00 p.m. on Wednesday, June 25, 2008.

**Review and Approval of the April 16-17, 2008 Board Meeting Minutes.** Ms. McManus moved to approve the minutes as drafted. Mr. Carr seconded the motion. The motion was carried by a vote of 8/0.

**Wyoming Professional Assistance Program (WPAP) Quarterly Report.** Mr. Vandel summarized the report for the second quarter of 2008 disseminated to the Board membership. Mr. Vandel also disseminated the 'Level I Relapse Behavior' letter used by WPAP when a client is deemed out of compliance with his/her Monitoring Agreement. Mr. Vandel discussed the procedure WPAP follows for subsequent non-compliance.

Ms. Walker thanked Mr. Vandel for allowing P4 students to shadow during their rotations.

**Medication Disposal.** Dr. Nelson presented a summary of her medication disposal initiative entitled, *Somebody Always Lives Downstream*, with the assistance of Maddie Wyatt, a P2 student at the University of Wyoming. During the discussion following the presentation, Roxanne Homar, State Pharmacist with the Wyoming Department of Health, said that she and Sen. Bob Fecht, Cheyenne Police Chief, worked together during the Cheyenne 'Day of Giving' in May and

offered a drop site for medication disposal. They received 500 pounds of prescription medications, 200 pounds of which were controlled substances. The Centralized Pharmacy in Cheyenne also has an increasing volume of inquiries regarding medication disposal.

Ms. Homar asked if there was interest in serving on a work group to investigate a legislative approach to the issue of medication disposal. Ms. Walker said that she would like to participate.

**Prescription Drug Monitoring Program (PDMP) Report.** Ms. Embury offered background on the initiation of the PDMP in Wyoming, which became operable in November, 2004, and a status report on current PDMP activity. Ms. Embury disseminated 1) a national summary of states with operational PDMPs, states with enacted PDMP legislation but not yet with an operational program, and states with legislation pending; and 2) a monthly activity report from July, 2004 through May, 2008.

**E-Prescribing CQI Initiative.** Ms. Walker summarized a memorandum received from the National Alliance of State Pharmacy Associations (NASPA) and SureScripts regarding their Continuous Quality Improvement (CQI) initiative for e-prescribing: the Pharmacy E-prescribing Experience Reporting (PEER) Portal.

**USP 797 Work Group.** Tim Seeley, Work Group Chair, reported to the Board via telephone. Mr. Seeley summarized the Work Group's activities. The Work Group concurs that USP 797 is the accepted standard of practice. From their research, the Work Group understands that the Board cannot defer to another legal entity's rules; it must write its own rules and regulations. Mr. Nelson said that there are provisions to adopt documents by reference, if they are unwieldy. Mr. Seeley said that UPS 797 is a massive Rule.

The Work Group suggests that a task force be convened to draft rules and regulations, comprised of pharmacists, health professionals, and other experts. Tom Murray, of the Pharmacy Compounding Accreditation Board (PCAB) has offered his assistance. Vendors have also offered their assistance. The Work Group identified the two most significant implementation challenges: assisting facilities to become compliant and monitoring their compliance.

Ms. Walker thanked Mr. Seeley for offering his leadership, expertise, time, and talent to the Work Group.

There was extensive discussion among the Board regarding USP 797. After discussion, the Board concluded that Sarah Blakely, Jennifer Nevins, and Mary Walker will begin with a thorough review of the National Association of Boards of Pharmacy (NABP) Model Rules applicable to USP 797 and will report back to the Board with their suggestions on how to proceed with a Rule drafting plan.

**Emergency Rule Extension.** Ms. Walker announced that the request for an extension of the Emergency Rule regarding pharmacists' authorization to prescribe and administer the Zoster vaccine has been signed by the Governor.

**NABP Annual Meeting.** Mr. Carr reported on the 104<sup>th</sup> Annual Meeting of the NABP, which was held in Baltimore, Maryland May 17-20, 2008. Mr. Carr served as the Board delegate; Ms. Walker served as the Board alternate delegate. Gary A. Schnabel, R.Ph., R.N., was named President-Elect. Mr. Schnabel is the Executive Director of the Oregon State Board of Pharmacy. The NABP passed eleven resolutions, including standardization of technician education standards.

**Security of Pharmacies.** Mr. Burton reported on his research regarding the physical security of pharmacies. Although intrusion detectors tied to local law enforcement are highly recommended for new pharmacies, the Rules do not address specific requirements for intrusion security. Mr. Burton researched companies that offer intrusion notification systems and summarized their cost and capability. Mr. Burton said that, although adding a video component to a system increases cost, it serves as a deterrent, especially with employees.

**Counterfeit Drugs.** Eric Hunter, University of Wyoming PharmD Candidate and Board of Pharmacy Intern, disseminated a summary of *Dangerous Doses*, a book written by investigative reporter Katherine Eban and published in 2005. Ms. Walker thanked Eric for his research, and said that it was impressive that he took the initiative to contact and interview Stephanie Feldman (Aleong), an attorney noted in the book who has prosecuted drug counterfeiters.

**Informational Items.** Ms. Walker disseminated the following material to the Board membership:

Correspondence from Kevin N. Nicholson, R.Ph., J.D., Vice President, Pharmacy Regulatory Affairs, National Association of Chain Drug Stores, dated June 2, 2008, regarding the Drug Enforcement Administration (DEA) response to Mr. Nicholson's inquiry regarding the DEA policy on "take-back" prescription disposal programs as they relate to controlled substances.

Course overview/description of Walgreen's Pharmacy Externship Program from Darlene Kaelin, Assistant Program Manager, Business Training and Development, Laramie County Community College, Cheyenne, Wyoming.

Correspondence from Clinical Supplies Management, Inc., Fargo, North Dakota, requesting an exemption from the reporting requirements for controlled substances. The company is licensed with the North Dakota Board of Pharmacy and with the DEA. The company does not dispense to patients; it packages, labels, and distributes clinical supplies (study drug and ancillary supplies) to investigators. The supplies are sent to clinical sites that have Institutional Review Board (IRB) approval. Patient data is unknown to the company. Ms. Walker will inform the company that their exemption request will be honored.

Correspondence from the Wyoming Healthcare Commission, dated June 3, 2008, regarding short-term recommendations of the Commission to the Joint Labor, Health, and Social Service Interim Committee in response to the Legislative Management Council's request to propose a way to systematically improve health care for low income citizens in Wyoming. Among the five recommendations is the allocation of initial funding for a statewide patient safety organization.

**WYOMING STATE BOARD OF PHARMACY**

**Board Meeting Minutes**

**June 25 and 26, 2008**

**Page 4 of 12**

Correspondence from Wendy P. Curran, Health Policy Advisor, dated June 19, 2008, regarding a petition from Concerned Women for America concerning distribution of controversial drugs. Ms. Walker said that the Governor's Office received hundreds of the pre-printed petitions and contacted the Agency to discern the source of the petition and to what Rules the petition may speak. Ms. Walker informed Ms. Curran that there are no pending Rules changes in Wyoming pertinent to the petition. The petition cites recent actions in 'Washington state and others'.

Overview, schedule, and general information regarding the NABP/AACP District VI/VII/VIII Annual Meeting, September 17-20, 2008, in Park City, Utah. Mr. Carr, Mr. Harrop, Ms. McManus, Ms. Nevins, Mr. Burton, and Mr. York expressed interest in attending the Annual Meeting.

**Agency Issues.** Ms. Walker introduced Jackie Seebaum, who was hired as the Executive Assistant to replace Karen Brannon upon her retirement.

Ms. Walker acknowledged Henry (Hank) York's five years of service to the Board.

Ms. Walker said that the Request for Proposals (RFP) has been sent for office space in Cheyenne. The deadline for response is July 2, 2008. The State reviews the responses for compliance with State requirements and then presents a list to the Agency, at which time site visits will be scheduled. Dr. Davis and Dr. Norwood volunteered to participate in the site visits, when possible. The RFP states September 1, 2008, or as soon thereafter as possible, for inception of the lease.

Ms. Walker presented Golden Certificates for pharmacists celebrating their 50<sup>th</sup> anniversary of licensure for Board signature. Mr. Carr and Ms. Nevins volunteered to present the Certificates at the Wyoming Pharmacy Association 91<sup>st</sup> Annual Convention.

**Board Meeting Dates.** After discussion, the Board agreed to convene for its next meeting at 1:00 p.m. in Lander on Wednesday, October 1, 2008, with anticipated adjournment at noon on Thursday, October 2, 2008.

**Open Agenda.** Kara Beach, Wyoming Pharmacy Association Executive Director, said that the American Pharmaceutical Association (APhA) has informed State Associations that The Medicare Improvements for Patients and Providers Act (H.R. 6331) will once again be presented for a vote tomorrow. The APhA has asked states to voice their support of the Bill to their Senate representatives.

**Adjournment to Executive Session.** Mr. Carr moved that the Board adjourn to Executive Session. Dr. Davis seconded the motion. The motion carried by a vote of 8/0. Mr. Harrop adjourned the Board to Executive Session.

**Return to Public Session.**

- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-10,  
Colleen E. Jones, R.Ph., Pharmacist License Number 2481.  
Ms. McManus moved to approve the referenced Agreement. Ms. Nevins seconded the motion. The motion carried by a vote of 8/0.
- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-09,  
Connie Lynne Werbelow, R.Ph., Pharmacist License Number 2301.  
Mr. McPherson moved not to approve the referenced Agreement. Mr. Carr seconded the motion. The motion carried by a vote of 6/2.
- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-08,  
Laurence Orren Trbovich, R.Ph., Pharmacist License Number 1881.  
Ms. McManus moved to approve the referenced Agreement. Mr. Smith seconded the motion. The motion carried by a vote of 8/0.
- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-13,  
Raymond Anton McRae, R.Ph., Pharmacist License Number 2091.  
Dr. Davis moved to approve the referenced Agreement. Dr. Norwood seconded the motion. The motion carried by a vote of 7/0; one Board member was recused from deliberation of the referenced Agreement.
- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-12,  
Steven G. Deane, R.Ph., Pharmacist License Number 2021.  
Mr. Carr moved to approve the referenced Agreement. Dr. Davis seconded the motion. The motion carried by a vote of 8/0.
- Re: Settlement Agreement, Stipulation and Order, Docket No. 08-11,  
Anne MacDonald Rahtjen, R.Ph., Pharmacist License Number 2781.  
Mr. Carr moved not to approve the referenced Agreement. Mr. McPherson seconded the motion. The motion carried by a vote of 6/2.
- Re: Request from Stacy M. Doak, R.Ph., dated May 20, 2008, to reduce provision of urine samples for substance testing from four times per month to two times per month.  
Dr. Norwood moved to grant Ms. Doak's request. Ms. Nevins seconded the motion. The motion carried by a vote of 8/0.

Mr. Harrop adjourned the meeting at 5:40 p.m. The meeting will reconvene at 9:00 a.m., Thursday, June 26, 2008.

**WYOMING STATE BOARD OF PHARMACY**  
**Public Hearing**  
**on Revisions to the**  
**Wyoming Pharmacy Act, Rules and Regulations**  
**Chapters 8, 10, and 16**

**Hearing Summary\***

**Thursday, June 26, 2008:**

Present/Absent	Board Member	Title
present	Randolph A. Harrop, R.Ph.	Board President
present	Alison Kay McManus, R.Ph.	Board Vice President
present	Terry L. Carr, R.Ph.	Board Secretary/Treasurer
present	Robert J. (Rick) Davis, M.D.	Board Member
absent	John R. McPherson, D.D.S.	Board Member
present	Jennifer S. Nevins, R.Ph.	Board Member
present	Gary W. Norwood, D.V.M.	Board Member
present	Charles W. Smith	Board Member
absent	Louann Weber, R.Ph.T.	Board Member, <i>ex-officio</i>

**Guests/Observers:**

Kara Beech, BS, CHC	Executive Director, Wyoming Pharmacy Association
H. Richard Burton, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy
Leith Culver	CareTrust IV - Casper, Wyoming
Eric Hunter	Intern; University of Wyoming PharmD Candidate
Ken F. Nelson, J.D.	Senior Assistant Attorney General
Marcus Prochazka	Lextron, Inc. - Greeley, Colorado
Skip Schneider	Lextron, Inc. - Greeley, Colorado
Jacqueline L. Seebaum	Executive Assistant, Board of Pharmacy
Mary K. Walker, R.Ph.	Executive Director, Board of Pharmacy
Henry (Hank) York, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy

**Public Hearing Call to Order.** Mr. Nelson called the Public Hearing to order at 9:00 a.m. with a court reporter present. Mr. Nelson asked if all guests had registered their name and intent to comment on the attendance sheet, then addressed each guest by name and asked if the guest wished to speak.

Skip Schneider, of Lextron, Inc., was the first to indicate he wished to speak. Mr. Schneider asked that Marcus Prochazka, also of Lextron, Inc. join him in addressing the Board. Mr. Schneider and Mr. Prochazka voiced their opposition to the deletion of the word “human” in Chapter 8, Section 3, as summarized in Mr. Prochazka’s June 9, 2008 correspondence to the Board.

Mr. Nelson queried the remaining guests; none wished to address the Board. Mr. Nelson closed the Public Hearing at 9:45 a.m. The court reporter was excused.

---

\* Please note that this is not the record of the Public Hearing and only serves as documentation for the Board’s meeting records.

**Thursday, June 26, 2008:**

Present/Absent	Board Member	Title
present	Randolph A. Harrop, R.Ph.	Board President
present	Alison Kay McManus, R.Ph.	Board Vice President
present	Terry L. Carr, R.Ph.	Board Secretary/Treasurer
present	Robert J. (Rick) Davis, M.D.	Board Member
absent	John R. McPherson, D.D.S.	Board Member
present	Jennifer S. Nevins, R.Ph.	Board Member
present	Gary W. Norwood, D.V.M.	Board Member
present	Charles W. Smith	Board Member
absent	Louann Weber, R.Ph.T.	Board Member, <i>ex-officio</i>

**Guests/Observers:**

Kara Beech, BS, CHC	Executive Director, Wyoming Pharmacy Association
H. Richard Burton, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy
Leith Culver	CareTrust IV - Casper, Wyoming
Eric Hunter	Intern; University of Wyoming PharmD Candidate
Ken F. Nelson, J.D.	Senior Assistant Attorney General
Jacqueline L. Seebaum	Executive Assistant, Board of Pharmacy
Mary K. Walker, R.Ph.	Executive Director, Board of Pharmacy
Henry (Hank) York, R.Ph.	Inspector/Compliance Officer, Board of Pharmacy

**Board Meeting Call to Order.** Mr. Harrop called the Board meeting to order at 10:00 a.m. on Thursday, June 26, 2008.

**Revisions to the Wyoming Pharmacy Act, Rules and Regulations, Chapter 8.** The Board reviewed, discussed, and voted upon the proposed Rules revisions as follows:

**Section 2**

Comment Received: None.

Action: Ms. Nevins moved to approve the April 16, 2008 revisions to Section 2 as drafted. Dr. Davis seconded the motion. The motion carried by a vote of 7/0.

**Section 3**

Comment Received: See Public Hearing Minutes.

See correspondence dated June 9, 2008 from Marcus Prochazka, Lextron, Inc., stating an objection to deletion of the word "human".

Ms. Walker received verbal comment from other states' veterinary drug compounders who objected to the proposed Rule revision.

Action: Dr. Davis moved that the April 16, 2008 revisions to Section 3. be rescinded and that Section 3. be approved as originally stated: "This Chapter applies to any person, partnership, corporation or business engaging in the wholesale distribution of human prescription drugs either into, out of, or within this State. "

Ms. Nevins seconded the motion. The motion carried by a vote of 7/0.

#### Section 4

Subsection: 4.d.  
Comment Received: None.  
Action: Mr. Carr moved that the April 16, 2008 revisions to Section 4.d. be amended to remove "or devices": (d) "Chain Pharmacy Warehouse" means a permanent physical location for prescription drugs that acts as a central warehouse and performs intracompany sales or transfers of prescription drugs ~~or devices~~ to chain pharmacies under common ownership and control. Chain pharmacy warehouses must be licensed as wholesale distributors.  
Ms. McManus seconded the motion. The motion carried by a vote of 7/0.

Subsection: 4.f.  
Comment Received: None.  
Action: Dr. Davis moved that the April 16, 2008 revisions to Section 4.f. be amended as follows: (f) "Counterfeit Drug" means a drug, ~~which, or~~ the container, shipping container, seal, or product labeling ~~of~~ which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, or device, or any likeness thereof, of a manufacturer, processor, packer, or distributor other than the person or persons who in fact manufactured, processed, packed, distributed, or wholesale distributed such drug and which thereby falsely purports or is represented to be the product of, or to have been packed, distributed, or wholesale distributed by such other manufacturer, processor, packer, or distributor.  
Mr. Carr seconded the motion. The motion carried by a vote of 7/0.

Subsection: 4.g.  
Comment Received: None.  
Action: Ms. Nevins moved that the April 16, 2008 revisions to Section 4.g. be amended as proposed by Dr. Davis: (g) "Drop Shipment" means the sale, by a manufacturer, that manufacturer's co-licensee, that manufacturer's third-party logistics provider, ~~or that manufacturer's exclusive distributor, of the manufacturer's prescription drug,~~ or by an authorized distributor of record that purchased the product directly from the manufacturer ~~or one of these entities,~~ to a wholesale distributor whereby the wholesale distributor takes title but not possession of such prescription drug. ~~and the~~ That wholesale distributor invoices the pharmacy, chain pharmacy warehouse, or other person authorized by law to dispense or administer ~~such a~~ drug to a patient. ~~and~~ †The pharmacy, chain pharmacy warehouse, or other authorized person ~~may~~ receives delivery of the prescription drug directly from the manufacturer, that manufacturer's co-licensee, that manufacturer's third-party logistics provider, ~~or that manufacturer's exclusive distributor, of such prescription drug, or from~~ an authorized distributor of record. ~~that purchased the product directly from the~~



~~manufacturer or one of these entities.~~ Drop shipments shall be part of the "Normal Distribution eChannel".

Dr. Norwood seconded the motion. The motion carried by a vote of 7/0.

Subsection: 4.k.

Comment Received: None.

Action: Mr. Carr moved that the April 16, 2008 revisions to Section 4.k. be amended as proposed by Dr. Davis: (k) "Normal Distribution Channel" means a chain of custody for a prescription drug that goes, directly or by drop shipment, from a manufacturer, ~~of the prescription drug,~~ the manufacturer's co-licensee, the manufacturer's third-party logistics provider, or the manufacturer's exclusive distributor to:

(i) an authorized distributor of record ~~and, subsequently,~~ to a pharmacy to a patient or other designated persons authorized by law to dispense or administer such prescription drug to a patient; or

(ii) an authorized distributor of record, ~~then~~ to a chain pharmacy warehouse ~~and, subsequently,~~ to that chain pharmacy warehouse's intracompany pharmacy to a patient or other designated persons authorized by law to dispense or administer such prescription drug to a patient; or

(iii) a chain pharmacy warehouse ~~and, subsequently,~~ to that chain pharmacy warehouse's intracompany pharmacy to a patient or other designated persons authorized by law to dispense or administer such prescription drug to a patient; or

(iv) an authorized distributor of record ~~and, subsequently,~~ to ~~one~~ other authorized distributors of record ~~who subsequently distribute~~ to an office-based healthcare practitioner authorized by law to dispense or administer such drug to a patient; or

(v) a pharmacy to a patient or other designated persons authorized by law to dispense or administer such prescription drug to a patient.

Ms. Nevins seconded the motion. The motion carried by a vote of 7/0.

Subsection: 4.n.(i)

Comment Received: None.

Action: Mr. Carr moved that the April 16, 2008 revisions to Section 4.n.(i) be amended to remove "or device": (i) ~~The sale, purchase or trade of a drug or an offer to sell, purchase or trade a drug for emergency medical reasons; for purposes of this section, "emergency medical reasons" includes transfers of prescription drugs by a retail pharmacy to another retail pharmacy to alleviate a temporary shortage, except that the gross dollar value of such transfers shall not exceed five (5) percent of the total prescription drug sales revenue of the transferor pharmacy during any twelve (12) consecutive month period; The sale, purchase, or trade of a prescription drug ~~or device,~~ an offer to sell, purchase, or trade pursuant to a prescription;~~

Ms. Nevins moved to adopt Section 4, as amended above. Mr. Carr seconded the motion. The motion carried by a vote of 7/0.

### **Section 5**

Comment Received: See correspondence dated April 15, 2008 from Robert L. Surovec, Regulatory Affairs Compliance Officer, PD-Rx Pharmaceuticals, Inc.

See correspondence dated April 23, 2008 from Gregory A. Conigliaro, General Manager, AmeriDose.

See correspondence dated May 13, 2008 from Trudi C. LeMaster, Regulatory Compliance Coordinator, BoundTree Medical.

See correspondence dated May 14, 2008 from Fabio Lanzieri, President, CURA Pharamceutical Company, Inc.

See correspondence dated May 29, 2008 from Steven B. Hauck, President and CEO, Diversified Healthcare Services.

See correspondence dated June 13, 2008 from Lis Houchen, Northwest Regional Director, State Government Affairs, National Association of Chain Drug Stores.

See correspondence dated June 23, 2008 from Chris Calenti, General Counsel, Methapharm, Inc.

Action: Ms. McManus moved to accept the April 16, 2008 revisions as drafted. Ms. Nevins seconded the motion. The motion carried by a vote of 7/0.

### **Section 6**

Comment Received: None.

Action: Ms. Nevins moved to accept the April 16, 2008 revisions as drafted. Dr. Davis seconded the motion. The motion carried by a vote of 7/0.

### **Section 7**

Comment Received: See correspondence dated June 13, 2008 from Lis Houchen, Northwest Regional Director, State Government Affairs, National Association of Chain Drug Stores.

Action: Mr. Carr moved to accept the April 16, 2008 revisions as drafted. Ms. Nevins seconded the motion. The motion carried by a vote of 7/0.

### **Section 8**

Comment Received: None.

Action: Dr. Norwood moved to accept the April 16, 2008 revisions as drafted. Ms. Nevins seconded the motion. The motion carried by a vote of 7/0.

**Section 9**

Comment Received: None.

Action: Mr. Carr moved to accept the April 16, 2008 revisions as drafted. Dr. Davis seconded the motion. The motion carried by a vote of 7/0.

**Section 10**

Comment Received: None.

Action: Ms. McManus moved to accept the April 16, 2008 revisions as drafted. Dr. Davis seconded the motion. The motion carried by a vote of 7/0.

**Section 11**

Comment Received: None.

Action: Dr. Norwood moved to accept the April 16, 2008 revisions as drafted. Ms. McManus seconded the motion. The motion carried by a vote of 7/0.

**Section 12**

Comment Received: None.

Action: Mr. Carr moved to accept the April 16, 2008 revisions as drafted. Dr. Norwood seconded the motion. The motion carried by a vote of 7/0.

**Section 13**

Comment Received: None.

Action: Ms. Nevins moved to accept the April 16, 2008 revisions as drafted. Ms. McManus seconded the motion. The motion carried by a vote of 7/0.

**Section 14**

Comment Received: None.

Action: Ms. McManus moved to accept the April 16, 2008 revisions as drafted. Mr. Carr seconded the motion. The motion carried by a vote of 7/0.

**Section 15**

Comment Received: None.

Action: Ms. Nevins moved to accept the April 16, 2008 revisions as drafted. Dr. Norwood seconded the motion. The motion carried by a vote of 7/0.

**Revisions to the Wyoming Pharmacy Act, Rules and Regulations, Chapter 10.** The Board reviewed, discussed, and voted upon the proposed Rules revisions as follows:

**Sections 10, 11, 12**

Comment Received: None.

Action: Ms. Nevins moved to accept the April 16, 2008 revisions as drafted. Ms. McManus seconded the motion. The motion carried by a vote of 7/0.

**Revisions to the Wyoming Pharmacy Act, Rules and Regulations, Chapter 16.** The Board reviewed, discussed, and voted upon the proposed Rules revisions as follows:

**Section 2**

Comment Received: None.

Action: Mr. Carr moved to accept the April 16, 2008 revisions as drafted. Ms. McManus seconded the motion. The motion carried by a vote of 7/0.

**Recognition.** Ms. Walker thanked H. Richard Burton and Henry (Hank) York for their efforts to make her transition into her role as Executive Director so positive and productive. Ms. Walker also commended them for the manner in which they conduct both inspections and investigations.

Mr. Harrop presented a draft Resolution in recognition of Trina Barber, Administrative Specialist, and Denise Embury, Records Analyst, for their dedicated service to the Board and their commitment to the Board during the transition. The membership approved the Resolution as drafted. Ms. Barber and Ms. Embury were invited to join the meeting. Mr. Harrop read the Resolution and presented a copy to Ms. Barber and Ms. Embury.

**Open Agenda.** Ms. Walker notified the membership that *USA Today* sent a questionnaire to which she has responded. The response included the names of the Board membership.

**Adjournment.** There being no further business brought before the Board, Mr. Harrop adjourned the meeting at 11:20 a.m.

Respectfully submitted,

*signature on file*

---

Jacqueline L. Seebaum  
Executive Assistant

Minutes reviewed:

*signature on file*

---

Mary K. Walker, R.Ph.  
Executive Director

Minutes approved and entered into the record:

*signature on file*

---

Randolph A. Harrop, R.Ph.  
Board President